重症感染患者抗菌药物降阶梯治疗与临床治愈评估:DIANA研究
DIANA研究为前瞻性观察性研究,纳入2016年10月至2018年5月期间28个国家152个ICU中接受经验性抗菌药物治疗的成人细菌感染患者,共1495例。降阶梯定义为经验性联合治疗中停用一种抗菌药物,或为缩窄抗菌谱而替换药物,且发生在治疗前3天内。结果示降阶梯、无改变和其他改变分别占16%、63%和22%;未调整28天死亡率降阶梯组15.8% vs 无改变组19.4%(P=0.27;RR 0.83,95%CI 0.60–1.14)。逆概率加权后,降阶梯组对比无降阶梯组的临床治愈相对危险估计为1.37(95%CI 1.14–1.64)。作者结论认为降阶梯在重症感染患者中应用较少,观察性效应估计提示降阶梯对比无降阶梯对临床治愈无有害影响,但可能存在残余混杂。
要点
- 在152个ICU的1495例成人细菌感染患者中,经验性治疗前3天内实施降阶梯者仅占16%,无改变占63%,其他改变占22%。
- 未调整28天死亡率:降阶梯组15.8% vs 无改变组19.4%(P=0.27;RR 0.83,95%CI 0.60–1.14),未达统计学显著。
- 逆概率加权后,降阶梯对比无降阶梯(无改变或其他改变)的第7天临床治愈相对危险估计为RR 1.37(95%CI 1.14–1.64)。
- 作者指出该观察性效应估计提示降阶梯对临床治愈无有害影响,但可能存在残余混杂。
适用人群与场景
- 28个国家152个ICU中接受经验性抗菌药物治疗的成人细菌感染患者,研究期为2016年10月至2018年5月。
诊断标准与关键阈值
- 降阶梯定义:在治疗前3天内,(1)经验性联合治疗时停用一种抗菌药物,或(2)为缩窄抗菌谱而替换一种抗菌药物。
研究设计与关键结果
- 研究类型:前瞻性观察性研究;样本量1495例成人ICU患者,来自28个国家152个ICU,研究期为2016年10月至2018年5月。
- 经验性联合治疗占50%,碳青霉烯类占26%;前3天内降阶梯、无改变和其他改变分别占16%、63%和22%。
- 未调整28天死亡率:降阶梯组15.8% vs 无改变组19.4%(P=0.27;RR 0.83,95%CI 0.60–1.14)。
- 逆概率加权后,降阶梯对比无降阶梯(无改变或其他改变)的临床治愈相对危险估计为RR 1.37(95%CI 1.14–1.64)。
证据类型、等级与局限
- 证据类型:前瞻性观察性研究;采用逆概率加权处理时间依赖混杂。
- 局限:作者指出可能存在残余混杂。
对床旁实践的改变
- 作者结论认为,降阶梯在重症感染患者中应用较少;观察性效应估计提示降阶梯对比无降阶梯对临床治愈无有害影响,但可能存在残余混杂。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: The DIANA study aimed to evaluate how often antimicrobial de-escalation (ADE) of empirical treatment is performed in the intensive care unit (ICU) and to estimate the effect of ADE on clinical cure on day 7 following treatment initiation.
METHODS: Adult ICU patients receiving empirical antimicrobial therapy for bacterial infection were studied in a prospective observational study from October 2016 until May 2018. ADE was defined as (1) discontinuation of an antimicrobial in case of empirical combination therapy or (2) replacement of an antimicrobial with the intention to narrow the antimicrobial spectrum, within the first 3 days of therapy. Inverse probability (IP) weighting was used to account for time-varying confounding when estimating the effect of ADE on clinical cure.
RESULTS: Overall, 1495 patients from 152 ICUs in 28 countries were studied. Combination therapy was prescribed in 50%, and carbapenems were prescribed in 26% of patients. Empirical therapy underwent ADE, no change and change other than ADE within the first 3 days in 16%, 63% and 22%, respectively. Unadjusted mortality at day 28 was 15.8% in the ADE cohort and 19.4% in patients with no change [p = 0.27; RR 0.83 (95% CI 0.60-1.14)]. The IP-weighted relative risk estimate for clinical cure comparing ADE with no-ADE patients (no change or change other than ADE) was 1.37 (95% CI 1.14-1.64).
CONCLUSION: ADE was infrequently applied in critically ill-infected patients. The observational effect estimate on clinical cure suggested no deleterious impact of ADE compared to no-ADE. However, residual confounding is likely.
参考来源
- De Bus L, Depuydt P, Steen J, et al. Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study. Intensive Care Med. 2020. PMID: 32519003. doi:10.1007/s00134-020-06111-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。